Tessa Braeckman

Tessa Braeckman

Auto-generated profile, based on publicly available information

Tessa Braeckman

Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2012 in BMJ
Verified
Journal Article
Open access
PDF file
TBTessa Braeckman
Tessa Braeckman
KHKoen Van Herck
Koen Van Herck
NMNadia Meyer
Nadia Meyer
JPJean-Yves Pirçon
Jean-Yves Pirçon
MSMontse Soriano-Gabarró
Montse Soriano-Gabarró
OGon behalf of the RotaBel Study Group
on behalf of the RotaBel Study Group
Objective To evaluate the effectiveness of rotavirus vaccination among young children in Belgium. Design Prospective case-control study. Setting Random sample of 39 Belgian hospitals, February 2008 to June 2010. Participants 215 children admitted to hospital with rotavirus gastroenteritis confirmed by polymerase chain reaction and 276 age and hospital matched controls. All children were of an eligible age to have received rotavirus vaccination (that is, born after 1 October 2006 and aged ≥14 weeks). Main outcome measure Vaccination status of children admitted to hospital with rotavirus gastroenteritis and matched controls. Results 99 children (48%) admitted with rotavirus gastroenteritis and 244 (91%) controls had received at least one dose of any rotavirus vaccine (P<0.001). The monovalent rotavirus vaccine accounted for 92% (n=594) of all rotavirus vaccine doses. With hospital admission as the outcome, the unadjusted effectiveness of two doses of the monovalent rotavirus vaccine was 90% (95% confidence interval 81% to 95%) overall, 91% (75% to 97%) in children aged 3-11 months, and 90% (76% to 96%) in those aged ≥12 months. The G2P[4] genotype accounted for 52% of cases confirmed by polymerase chain reaction with eligible matched controls. Vaccine effectiveness was 85% (64% to 94%) against G2P[4] and 95% (78% to 99%) against G1P[8]. In 25% of cases confirmed by polymerase chain reaction with eligible matched controls, there was reported co-infection with adenovirus, astrovirus and/or norovirus. Vaccine effectiveness against co-infected cases was 86% (52% to 96%). Effectiveness of at least one dose of any rotavirus vaccine (intention to vaccinate analysis) was 91% (82% to 95%). Conclusions Rotavirus vaccination is effective for the prevention of admission to hospital for rotavirus gastroenteritis among young children in Belgium, despite the high prevalence of G2P[4] and viral co-infection.

1 January 2009 in Cytotherapy
Verified
Journal Article
Closed access
PDF file
ADAnn Van Driessche
Ann Van Driessche
AVAnn L.R. Van de Velde
Ann L.R. Van de Velde
GNGriet Nijs
Griet Nijs
TBTessa Braeckman
Tessa Braeckman
BSBarbara Stein
Barbara Stein
VTViggo Van Tendeloo
Viggo Van Tendeloo
RNA-electroporated dendritic cell (DC)-based vaccines are rapidly gaining interest as therapeutic cancer vaccines. We report on a phase I dose-escalation trial using clinical-grade manufactured mature RNA-electroporated DC in acute myeloid leukemia (AML) patients. CD14+ cells were isolated from leukapheresis products by immunomagnetic CliniMACS separation and differentiated into mature DC (mDC). mDC were electroporated with clinical-grade mRNA encoding the Wilm's tumor (WT1) antigen, and tested for viability, phenotype, sterility and recovery. To test product safety, increasing doses of DC were administered intradermally four times at 2-week intervals in 10 AML patients. In a pre-clinical phase, immunomagnetic monocyte isolation proved superior over plastic adherence in terms of DC purity and lymphocyte contamination. We also validated a simplified DC maturation protocol yielding a consistent phenotype, migration and allogeneic T-cell stimulatory capacity in AML patients in remission. In the clinical trial, highly purified CD14+ cells (94.5 ± 3.4%) were obtained from all patients. A monocyte-to-mDC conversion factor of 25 ± 10% was reached. All DC preparations exhibited high expression of mDC markers. Despite a decreased cell recovery of mDC after a combination of mRNA electroporation and cryopreservation, successful vaccine preparations were obtained in all AML patients. DC injections were well tolerated by all patients. Our method yields a standardized, simplified and reproducible preparation of multiple doses of clinical-grade mRNA-transfected DC vaccines from a single apheresis with consistent mature phenotype, recovery, sterility and viability. Intradermal injection of such DC vaccines in AML patients is safe.

1 April 2014 in Vaccine
Verified
Journal Article
Closed access
KMKirsten Maertens
Kirsten Maertens
SSSara De Schutter
Sara De Schutter
TBTessa Braeckman
Tessa Braeckman
LBLesley Baerts
Lesley Baerts
PDPierre Van Damme
Pierre Van Damme
ELElke Leuridan
Elke Leuridan

1 January 2011 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
TBTessa Braeckman
Tessa Braeckman
KHKoen Van Herck
Koen Van Herck
MRMarc Raes
Marc Raes
AVAnne Vergison
Anne Vergison
MSMartine Sabbe
Martine Sabbe
PDPierre Van Damme
Pierre Van Damme
: The current Belgian experience with rotavirus vaccination provides a unique perspective to look at the effect of vaccination. Shortly after introduction, a nation-wide recommendation was issued and despite the fact that both rotavirus vaccines are offered through partial reimbursement, vaccine uptake has already reached a high level (at least 90%). : For the purpose of looking at the effectiveness of the Belgian rotavirus vaccination policy, 3 years after introduction, we retrospectively collated the publicly available data on the number of laboratory-confirmed rotavirus cases reported to a national network of sentinel laboratories during 1999 to 2010 and compared them with the available data on hospitalizations due to rotavirus gastroenteritis. : Both data sources (reported laboratory-diagnosed cases to a sentinel network as well as data on hospitalizations due to rotavirus gastroenteritis) show a decrease in the number of rotavirus infections and a 4- to 6-week delay in the onset of disease and the peak of incidence in the postvaccination period. : Because this decline coincides with the increased vaccine uptake and is sustained during consecutive rotavirus seasons, the effect is mainly attributed to the rotavirus vaccination. The rapid increase in vaccine coverage, despite the partial reimbursement for the vaccines, is remarkable. Continued postlicensure surveillance is necessary to further investigate the effectiveness of the vaccines and to document the public health impact of the vaccination in reducing disease burden.

1 January 2014 in Vaccine
Verified
Journal Article
Closed access
TLTinne Lernout
Tinne Lernout
HTHeidi Theeten
Heidi Theeten
NHNiel Hens
Niel Hens
TBTessa Braeckman
Tessa Braeckman
MRMathieu Roelants
Mathieu Roelants
PDPierre Van Damme
Pierre Van Damme

1 November 2016 in Vaccine
Verified
Journal Article
Closed access
KMKirsten Maertens
Kirsten Maertens
TBTessa Braeckman
Tessa Braeckman
GTGeert Top
Geert Top
PDPierre Van Damme
Pierre Van Damme
ELElke Leuridan
Elke Leuridan